Realm discontinues development of allergic conjunctivitis candidate

Realm Therapeutics plc (AIM:RLM) discontinued development of allergic conjunctivitis candidate PR013 after the product “did not demonstrate efficacy” in a Phase II trial in about 90 patients. The product is a topical ophthalmic solution containing a high concentration of hypochlorous acid...